, Tracking Stock Market Picks
Enter Symbol:
Myriad Genetics, Inc. (MYGN) [hlAlert]

up 92.71 %

Myriad Genetics, Inc. (MYGN) upgraded to Buy with price target $24 by Auriga

Posted on: Monday,  Sep 12, 2011  8:25 AM ET by Auriga

Auriga rated Buy Myriad Genetics, Inc. (NASDAQ: MYGN) on 09/12/2011, when the stock price was $18.40. Since
then, Myriad Genetics, Inc. has gained 92.72% as of 01/21/2016's recent price of $35.46.
If you would have followed this Auriga's recommendation on MYGN, you would have gained 92.71% of your investment in 1592 days.

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.

Auriga operates full-service institutional equity and fixed income trading desks with state-of-the-art communications technology and trading systems. Through our U.S. corprate parent, Auriga Holdings, LLC we offer a variety of services including whole loan trading and asset management. Through our Spanish parent company, Auriga Securities Sociedad de Valores, S.A., we offer the ability to trade European equity and fixed income products. We connect electronically to buy-side firms; route orders to multiple points of execution and subsequently route to our clearing firm, Pershing, for settlement.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/12/2011 8:25 AM Buy
18.40 24.00
as of 12/30/2011
1 Week up  3.10 %
1 Month down  -1.45 %
3 Months up  11.73 %
1 YTD up  13.80 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/15/2011 8:25 AM Hold
23.67 25.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy